Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge ADVISES Tele2 IN CONNECTION WITH SALE OF CABLE AND FIBRE OPERATIONS
Mandate

Vinge ADVISES Tele2 IN CONNECTION WITH SALE OF CABLE AND FIBRE OPERATIONS

October 23, 2013

Vinge is advising Tele2 in connection with the sale of its cable and fibre operations on the private market and the private customers pertaining thereto to Telenor. The total cash consideration amounts to SEK 794 million of which approximately SEK 250 constitutes capital gains. The transaction relates to approximately 125 000 fixed broadband customers and approximately 75 000 digital TV customers. Telenor’s acquisition is subject to the approval of the Swedish Competition Authority.

Partner Johan Winnerblad together with, among others, associates Nina Farrahi, Mikael Satama Granberg and Jonatan Lund Kirkhoff are advising Tele2. Partner Johan Karlsson and associate Grant McKelvey are providing competition law advice and associate Åsa Gotthardsson is providing employment law advice.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025